JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3017 Dasatinib (BMS-354825)
4 Citation

Summary: Src and BCR-Abl inhibitor

≥24.4 mg/mL
A3660 Nilotinib monohydrochloride monohydrate

Summary: Bcr-Abl inhibitor

≥50 mg/mL
A8603 GNF 2

Summary: Bcr-Abl inhibitor

insoluble in H2O; ≥18.7 mg/mL
A8604 GNF 5

Target: Bcr-Abl

Summary: Bcr-Abl inhibitor
A8605 1-Naphthyl PP1

Summary: Src family kinases inhibitor

≥25.32 mg/mL
A8606 PD 180970

Summary: P210bcr/abl tyrosine kinase inhibitor

<21.46 mg/mL
A8607 PPY A

Target: Abl kinases

Summary: Abl kinases inhibitor

<37.24 mg/mL
A8812 PD173955

Target: Bcr-Abl|Src

Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,

≥22.15 mg/mL
B1011 Bafetinib (INNO-406)
2 Citation

Summary: Bcr-Abl/Lyn tyrosine kinase inhibitor

≥57.7 mg/mL
B1404 DCC-2036 (Rebastinib)

Target: FLT3|Bcr-Abl|Tie-2|KDR

Summary: Bcr-Abl inhibitor

≥27.7 mg/mL